Latest news with #RobbinsGeller
Associated Press
42 minutes ago
- Business
- Associated Press
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. (ZBIO) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the 'IPO') held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma's top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Zenas BioPharma class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Zenas BioPharma is a clinical-stage biopharmaceutical company that engages in the development and commercialization of transformative immunology-based therapies. According to the complaint, in its IPO, Zenas BioPharma sold over 13 million shares at $17.00 per share. The Zenas BioPharma class action lawsuit alleges that the IPO's offering documents were materially false and/or misleading and/or failed to disclose that Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. The Zenas BioPharma class action lawsuit further alleges that on November 12, 2024, Zenas BioPharma filed its quarterly report for the period ended September 30, 2024, disclosing that Zenas BioPharma could fund it operations for the following 12 months, not 24 months, as Zenas BioPharma had stated in the IPO's registration statement. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement issued in connection with the IPO to seek appointment as lead plaintiff in the Zenas BioPharma class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Zenas BioPharma class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Zenas BioPharma class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Zenas BioPharma class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Associated Press
2 days ago
- Business
- Associated Press
SATS INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into EchoStar Corporation and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
SAN DIEGO--(BUSINESS WIRE)--Jun 5, 2025-- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar Corporation (NASDAQ: SATS) focused on whether EchoStar and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the EchoStar investigation or if you are an EchoStar investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneysJ.C. SanchezorJennifer N. Caringalof Robbins Geller by calling 800/449-4900 or via e-mail at[email protected]. THE COMPANY: EchoStar, together with its subsidiaries, provides networking technologies and services. THE REVELATIONS: On May 12, 2025, The Wall Street Journal published an article entitled 'FCC Threatens Charlie Ergen's Hold on Satellite, 5G Spectrum Licenses,' reporting that '[t]he Federal Communications Commission told Ergen, the chairman and co-founder of network operator EchoStar, that the agency's staff would investigate the company's compliance with federal requirements to build a nationwide 5G network.' Following this news, the price of EchoStar stock fell more than 16%. Then, on May 30, 2025, EchoStar disclosed that it had 'elected not to make an approximately $326 million cash interest payment due on May 30, 2025' in order 'to allow time for the FCC to provide the relief requested in our Response prior to the expiration of the 30-day grace period, so that we may confidently continue investing in our network buildout and expansion of our Boost business and [mobile-satellite service].' Following this news, the price of EchoStar stock fell an additional 12%. And on June 2, 2025, EchoStar similarly revealed that '[i]n light of the uncertainty raised by the Federal Communications Commission ('FCC') review disclosed . . ., EchoStar . . . has elected not to make approximately $183 million in cash interest payments due on June 2, 2025' in order 'to allow time for the FCC to provide the relief requested in our FCC filing prior to the expiration of the 30-day grace period.' Following this news, the price of EchoStar stock fell more than 11%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. View source version on CONTACT: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Robbins Geller Rudman & Dowd LLP Copyright Business Wire 2025. PUB: 06/05/2025 07:15 AM/DISC: 06/05/2025 07:15 AM
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
ABL INVESTIGATION ALERT: Investigation Launched into Abacus Global Management, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO, June 4, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Abacus Global operates as an alternative asset manager and market maker. THE REVELATION: On June 4, 2025, Morpheus Research published a report titled 'Abacus Global Management: This $740 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die.' On this news, Abacus Global's stock price fell more than 21%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Malaysian Reserve
5 days ago
- Business
- Malaysian Reserve
NOTICE: Investors File Class Action Lawsuit Against Broadmark Realty Capital Inc., Ready Capital Corporation, Others and Attorneys Announce Opportunity for Investors with Substantial Losses to Lead Cl
SAN DIEGO, June 2, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that holders of Broadmark Realty Capital Inc. (NYSE: BRMK) common stock as of the record date of the May 2023 merger between Broadmark and Ready Capital Corporation (NYSE: RC) ('Merger'), have until July 28, 2025 to seek appointment as lead plaintiff of the Broadmark class action lawsuit. Captioned Grant v. Broadmark Realty Capital, No. 25-cv-01013 (W.D. Wash.), the Broadmark class action lawsuit charges Broadmark, Ready Capital, certain of Broadmark's and Ready Capital's top executives and directors, and Ready Capital's external asset manager with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Broadmark class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Broadmark and Ready Capital are real estate investments trusts. On May 30, 2023, Broadmark shareholders voted to approve the merger of Broadmark and Ready Capital, which closed the next day. The Broadmark class action lawsuit alleges that the proxy statement used to solicit the support of Broadmark shareholders for the Merger contained false and/or misleading statements and/or failed to disclose that: (i) a material portion of borrowers within Ready Capital's originated portfolio were experiencing significant financial distress due to high interest rates that had increased their borrowing costs; (ii) an oversupply of multifamily properties in Ready Capital's markets of operation had severely limited the ability of Ready Capital borrowers to raise their rents by the amounts necessary to cover their growing debt costs; (iii) a major development project acquired in Ready Capital's acquisition of Mosaic Real Estate Credit, LLC, Mosaic Real Estate Credit TE, LLC, and MREC International Incentive Split, LP (a Ritz-Carlton located in Portland, Oregon), which accounted for approximately $500 million of Ready Capital's acquired loan portfolio, had experienced catastrophic setbacks since its inception, including significant cost overruns, construction delays, and funding shortfalls; (iv) as a result, Ready Capital's Current Expected Credit Loss reserves and expected credit losses were materially understated; and (v) consequently, Ready Capital's financial projections regarding Ready Capital's Distributable Earnings per share, dividends per share, and book value per share had no basis in fact when made. The price of Ready Capital stock has remained significantly below the Merger price as of the time the Broadmark class action lawsuit was filed. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who held Broadmark common stock as of the record date of the Merger to seek appointment as lead plaintiff in the Broadmark class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Broadmark class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Broadmark class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Broadmark class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
Associated Press
29-05-2025
- Business
- Associated Press
OGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--May 29, 2025-- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon and certain of Organon's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide your information here: You can also contact attorneysJ.C. SanchezorJennifer N. Caringalof Robbins Geller by calling 800/449-4900 or via e-mail at[email protected]. Lead plaintiff motions for the Organon class action lawsuit must be filed with the court no later than July 22, 2025. CASE ALLEGATIONS: Organon develops and delivers health solutions through prescription therapies and medical devices. The Organon class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants concealed material information pertaining to Organon's capital allocation priorities, particularly the future of the quarterly dividend payout; (ii) in truth, Organon's optimistic reports of the dividend payout as Organon's 'number one priority' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; and (iii) Organon planned to prioritize debt reduction following Organon's acquisition of Dermavant Sciences Ltd. The Organon class action lawsuit further alleges that on May 1, 2025, Organon reported first quarter 2025 financial results and announced that management reset Organon's dividend payout from $0.28 to $0.02. On this news, the price of Organon stock fell more than 27%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Organon securities during the class period to seek appointment as lead plaintiff in the Organon class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Organon class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Organon class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Organon class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. View source version on CONTACT: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Robbins Geller Rudman & Dowd LLP Copyright Business Wire 2025. PUB: 05/29/2025 09:25 AM/DISC: 05/29/2025 09:24 AM
